Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2025-11-06 Major Shareholding Noti…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 7 pages 464.8KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and is a 'Notice of initial substantial holder' under the Corporations Act 2001, Section 671B. It details the substantial shareholding of Firetrail Investments Pty Ltd in PYC Therapeutics Ltd, including voting power, relevant interests, registered holders, consideration paid for shares, and associates. The document is a regulatory filing notifying the market and regulators about a substantial shareholding crossing a threshold. It is not a financial report, earnings release, or management report. It fits the definition of a Major Shareholding Notification (MRQ). The document length is over 11,000 characters, indicating it is a full notice, not a brief announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2025-11-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 594.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 2025 SHAREHOLDER UPDATE' and provides detailed progress updates on the company's drug development pipeline, clinical trial progress, and expected milestones for upcoming quarters and years. It includes financial information such as cash on hand and expected R&D rebates, as well as related party payments disclosed in an Appendix 4C quarterly cash flow report. The content is comprehensive and covers a quarter's operational and financial performance, consistent with a quarterly or interim report. There is no indication that this is a full annual report (10-K), nor is it a brief earnings release or a simple announcement. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-10-26 English
ADOA Program Initiation of Global Repeat Dose Study 4 pages 314.6KB
Regulatory Filings Classification · 90% confidence The document is an announcement dated 21 October 2025 from PYC Therapeutics Limited about the initiation of a global repeat dose Phase 1b clinical study for their drug candidate PYC-001 targeting Autosomal Dominant Optic Atrophy (ADOA). It details the study design, objectives, dosing cohorts, and next steps including future clinical trials. The content is focused on clinical trial progress and drug development updates rather than financial results, regulatory filings, or shareholder information. There is no indication of financial data, earnings, management changes, or regulatory certifications. The document is a corporate announcement about a clinical trial initiation, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a presentation or a call transcript. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories, since it is a company announcement about clinical development progress.
2025-10-20 English
Notice of Annual General Meeting/Proxy Form 17 pages 739.7KB
AGM Information Classification · 95% confidence The document is an announcement and detailed notice regarding the 2025 Annual General Meeting (AGM) of PYC Therapeutics Limited. It includes the date and location of the AGM, instructions for shareholders on voting and proxy submission, the agenda including the presentation of the Annual Report, resolutions to be voted on (such as the Remuneration Report and director re-elections), and explanatory notes. The document does not contain the actual Annual Report or financial statements but refers shareholders to the company's website to access the Annual Report. It also includes proxy forms and voting instructions, typical of AGM notices and materials. The document is comprehensive and lengthy (15,000 characters), consistent with AGM Information filings. Therefore, the document fits the category of AGM Information (AGM-R) rather than the Annual Report (10-K) or Remuneration Information (DEF 14A).
2025-10-16 English
Investor Webinar Presentation 6 pages 426.5KB
Investor Presentation Classification · 95% confidence The document is a presentation dated October 2025 from PYC Therapeutics Limited, providing updates on business activities including recent board and management changes, drug development pipeline progress, commercialisation, and capital management plans. It is structured as a slide deck with agenda points and detailed program objectives, typical of an investor presentation. There is no indication of it being a formal report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript or regulatory filing. The content focuses on strategic updates and forward-looking statements aimed at investors. Therefore, the document fits the definition of an Investor Presentation (IP). The document length (5294 characters) supports it being a full presentation rather than a brief announcement or certification.
2025-10-12 English
PMS Program Data Supports Progression to Human Trials 7 pages 1.7MB
Capital/Financing Update Classification · 95% confidence The document is an announcement from PYC Therapeutics about pre-clinical data supporting progression to human trials for a drug candidate targeting Phelan-McDermid Syndrome. It includes detailed scientific data, study results, and future clinical trial plans. The content is focused on drug development progress and scientific findings rather than financial results, regulatory certifications, or shareholder information. It is not a full financial report, earnings release, or regulatory filing. The document is a detailed update on capitalizing on research and development progress, which aligns with a Capital/Financing Update (CAP) category as it relates to advancing a drug candidate towards clinical trials, a key financing and development milestone for a biotech company. The document length and detail confirm it is not a brief announcement or a report publication announcement. Therefore, the best fit is Capital/Financing Update (CAP).
2025-10-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.